Disease relevance of Leukemia, Hairy Cell

• The B lymphoproliferative disorders B chronic lymphocytic leukemia (B-CLL) and hairy cell leukemia (HCL) produce a number of autocrine growth factors, including tumor necrosis factor (TNF), interleukin 6 (IL-6), and IL-1, all of which may induce positive feedback growth loops [1].
• The mechanisms that lead to reticulin fibrosis of bone marrow (BM) in hairy cell leukemia (HCL) are not fully understood [2].
• Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine [3].
• CD11c (LEU-M5) expression characterizes a B-cell chronic lymphoproliferative disorder with features of both chronic lymphocytic leukemia and hairy cell leukemia [4].
• Immunoglobulin gene rearrangement analysis and somatic cell hybridization techniques were used to examine the malignant cell population in an unusual patient with hairy cell leukemia and macroglobulinemia (N Engl J Med 296:92, 1977) [5].

High impact information on Leukemia, Hairy Cell

• CONCLUSIONS: BL22 can induce complete remissions in patients with hairy-cell leukemia that is resistant to treatment with purine analogues [6].
• More on the association of glucose-6-phosphate dehydrogenase deficiency with hairy-cell leukemia [7].
• Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine [8].
• Lengthy follow-up will be required to determine a median duration for the responses of hairy-cell leukemia to pentostatin [9].
• Lithium in hairy-cell leukemia [10].

Chemical compound and disease context of Leukemia, Hairy Cell

• Newer purine analogues for the treatment of hairy-cell leukemia [11].
• In sections of the spleen, the leukemic cells diffusely infiltrated the red pulp in a pattern strikingly similar to that of hairy cell leukemia; however, when the leukemic cells were studied cytochemically, the cytoplasmic acid phosphatase positivity was punctate and tartrate-sensitive [12].
• Treatment of hairy cell leukemia (leukemic reticuloendotheliosis) II. Chlorambucil therapy in postsplenectomy patients with progressive disease [13].
• Increased cholesterol biosynthesis in leukemic cells from patients with hairy cell leukemia [14].
• Two patients with hairy cell leukemia treated with the anthracycline antibiotic rubidazone are presented [15].

Biological context of Leukemia, Hairy Cell

• Treatment of hairy cell leukemia with recombinant alpha interferon: II. In vivo down-regulation of alpha interferon receptors on tumor cells [16].
• Among chronic lymphoproliferative disorders other than MCL, only 1 atypical chronic lymphocytic leukemia (CLL) with a t(11;14) translocation and bcl-1 rearrangement and the 2 hairy cell leukemias (HCLs) analyzed showed upregulation of PRAD-1 gene [17].
• In hairy cell leukemia (HCL) the malignant cells display a highly characteristic tissue distribution in which interactions with extracellular matrix (ECM) are often prominent [18].
• Phosphorylation of CD20 in cells from a hairy cell leukemia cell line. Evidence for involvement of calcium/calmodulin-dependent protein kinase II [19].
• OBJECTIVE: To review the pharmacology, pharmacokinetics, adverse effects, and various dosage regimens of pentostatin, and to evaluate the role of pentostatin in the treatment of hairy cell leukemia (HCL) [20].

Anatomical context of Leukemia, Hairy Cell

• Establishment of a hairy cell leukemia cell line carrying Tac antigen and phagocytic activity with B-cell characteristics [21].
• Patients with leukemic reticuloendotheliosis or "hairy cell leukemia" characteristically had low percentages of CRL but normal or increased percentages of surface immunoglobulin-positive lymphocytes [22].
• Some B-cell neoplasms, including hairy cell leukemia (HCL), lack expression of the adhesion molecule leukocyte function antigen-1 (LFA-1/CD11a) [23].
• LeuM5 antigen (CD11c, p150.95) expression, widely used as an immunodiagnostic marker for B-cell hairy cell leukemia, was examined on benign, normal peripheral blood T cells before and after stimulation in vitro with phytohemagglutinin and on a large, diverse panel of 73 T-cell neoplasms [24].
• The nucleotide analogue 2-chlorodeoxyadenosine (2-CdA), which induces excellent clinical responses in hairy cell leukemia, is known to suppress helper T cells; therefore, we used 2-CdA, alone or in combination with cytarabine, to treat patients with idiopathic HES [25].

Gene context of Leukemia, Hairy Cell

• Although hairy cell leukemia is uniquely sensitive to interferon-alpha (IFN-alpha), the biologic basis for this phenomenon remains unclear [26].
• Phenotypic analysis of hairy cell leukemia: "variant" cases express the interleukin-2 receptor beta chain, but not the alpha chain (CD25) [27].
• Expression and activity of NOX5 in the circulating malignant B cells of hairy cell leukemia [28].
• RESULTS: 8/11 mantle cell lymphomas, 0/11 chronic lymphocytic leukemias, 0/4 hairy cell leukemias, 0/2 Sezary syndrome, 0/2 monocytoid B-cell lymphomas, 0/3 follicular lymphomas, and 0/2 reactive hyperplasias had overexpression of cyclin D1 [29].
• Expression of the IL2 receptor alpha, beta and gamma chains in hairy cell leukemia [30].

Analytical, diagnostic and therapeutic context of Leukemia, Hairy Cell

• Efficacy of 2'-deoxycoformycin in hairy-cell leukemia: a study of the National Cancer Institute of Canada Clinical Trials Group [31].
• Two patients with progressive hairy cell leukemia following splenectomy were treated with low-dose daily chlorambucil [32].
• PURPOSE: To determine the role of computed tomography (CT) in patients with hairy cell leukemia (HCL), we report a series of 43 patients prospectively evaluated for internal adenopathy by CT before and after treatment with 2-chlorodeoxyadenosine (2-CdA) [33].
• Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia [34].
• We have investigated the direct effects of interferon (IFN) on hairy cells (HCs) isolated from patients with hairy cell leukemia using one- and two-dimensional gel electrophoresis [35].

References